Key result
Admission HbA1c levels are linked to 2-year CV mortality and MACE in post-PCI STEMI patients.
Why the study?
Does admission HbA1c level predict short-term and long-term mortality and morbidity in STEMI patients undergoing primary PCI?
Population
796 consecutive patients with ST-segment elevation myocardial infarction undergoing primary percutaneous…
Comparison
Admission HbA1c levels vs Comparison across the three HbA1c groups
Design
Cohort
Follow-up
2 years
Authors
Loading...
May support risk stratification after primary PCI in STEMI; extends observational data but leaves causal role and intervention effects open.
Cohort (n=796)
Does admission HbA1c level predict short-term and long-term mortality and morbidity in STEMI patients undergoing primary PCI?
p-value: p=<0.001
Admission HbA1c is an independent predictor of in-hospital and 2-year mortality and morbidity in STEMI patients treated with primary PCI.
Çiçek et al. (2016) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=796). Admission hemoglobin A1c (HbA1c) levels vs. Lower HbA1c levels (≤5.6%) was evaluated on 2-year primary clinical outcomes, including cardiovascular mortality, heart failure/shock, and major adverse cardiovascular event (p=<0.001). Admission HbA1c levels were significantly associated with 2-year cardiovascular mortality, heart failure/shock, and major adverse cardiovascular events in STEMI patients after primary PCI (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: